Inspiremd Inc NSPR

$0.64 -0.13 (-16.78%)

Valuation

Market cap
35,982,000
Revenue TTM
$8,980,000
Net income TTM
$-48,790,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-543.32%
Debt to equity
0.00

Trading

Volume
1,297,900
Avg volume
243,424
Day's range
$0.45 – $0.66
Shares out
46,489,000
Stochastic %K
52%
Beta
0.92
Analysts
Strong Buy
Price target
$3.33

Price

Company profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic preven...

Show more

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.

Industry
Medical Devices
Sector
Healthcare
Phone
888 776 6804
Website
https://www.inspiremd.com
Address
6303 Waterford District Drive, Suite 215, Miami, United States

Latest news

Stocktwits

BioBuddha Nov 13, 8:56 PM
$NSPR the best thing that could happen is big medtech buys them for 3x one year from now. In one year the price could go up to 1.5. So after that a buyout could be between 3-5
0 replies
Stasis09 Nov 13, 7:25 PM
$NSPR - Geez, the company’s management continues to stumble around in the dark! In the interim it’s only gotten more difficult for any company to gain product access into an OR or Angio suite with a one trick pony. Hospitals today demand pricing and discounts on a catalog of products from a company. They simply say “no” to the best in class stent if they deem the cost prohibitive. Surely Slosman et al must understand this concept. However, as long as he continues to fiscally benefit, there is little motivation to sell the company or partner with one of the larger medical device companies to leverage their hospital access, sales reps, and catalogue pricing. I don’t see this ending well!
0 replies
BioBuddha Nov 13, 4:16 PM
$NSPR people are really stupid. They beat on margins and revenue both. They got approvals . Now 2027 is all progress. And the market beats this 25%. This is a screaming buy
2 replies
matthew122 Nov 13, 3:00 PM
$NSPR this is a great deal. Company is now well capitalized with TCAR approval heading into commercialization. Very excellent.
0 replies
rcarigl23 Nov 13, 2:38 PM
$NSPR really F …. ed here…. 0,30 at least
1 replies
Thespectator Nov 13, 2:24 PM
$NSPR told you this is a perpetual dilution and r/s scheme, now they are issuing approximately 50m new shares coupled with new warrants you can bet r/s is inbound
0 replies
SecoTrader Nov 13, 2:11 PM
$NSPR so what is the pricing structure of the offering? The PR does not say anything about exercise price for warrants, etc right???? Sounds quite suicidal at first sight
0 replies
OpenOutcrier Nov 13, 1:42 PM
$NSPR (-15.6% pre) InspireMD prices $37.5M public offering of shares and warrants https://ooc.bz/l/121168
0 replies